Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA; Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic.
J Control Release. 2021 May 10;333:139-150. doi: 10.1016/j.jconrel.2021.03.028. Epub 2021 Mar 25.
Pancreatic ductal adenocarcinoma (PDAC) is a growing medical problem associated with extensive metastasis and high mortality. Intraperitoneal (IP) administration of therapeutics promises to help the treatment of cancers originated from organs in the peritoneal cavity. In this study, we evaluated how physicochemical properties of self-assembled polycation/siRNA nanoparticles affect their IP delivery efficacy in an orthotopic PDAC model. We have examined the effect of covalent polycation modification with lipophobic and hydrophobic tetrafluoro-p-toluic acid (TFTA), hydrophobic cholesterol, and hydrophilic poly(ethylene glycol) respectively. The surface charge of the three different nanoparticles was also modulated by coating the surface with serum albumin. We found that positively charged fluorine-containing particles with lipophobic properties based on a mixture of positively charged polymeric AMD3100 CXCR4 antagonist (PAMD) and PAMD modified with TFTA (mPAMD-TFTA)/siRNA displayed the best cell uptake and transfection efficacy in vitro. Biodistribution evaluation of the nanoparticles in a syngeneic orthotopic PDAC model revealed that the fluorine-containing formulation also achieved the highest PDAC tumor accumulation after IP administration. With a combination of CXCR4 inhibition by PAMD and PLK1 downregulation by siRNA, the treatment with mPAMD-TFTA/siPLK1 showed significant inhibition of both primary and metastatic PDAC tumors. Overall, our study provides insights into and guides the design of the nanoparticles for improved IP delivery of siRNA in PDAC.
胰腺导管腺癌(PDAC)是一个日益严重的医学问题,与广泛转移和高死亡率有关。腹腔内(IP)给药治疗有望有助于治疗源于腹腔内器官的癌症。在这项研究中,我们评估了自组装聚阳离子/ siRNA 纳米颗粒的物理化学性质如何影响其在原位 PDAC 模型中的 IP 递药效果。我们研究了分别用疏水性和疏脂性四氟对甲苯酸(TFTA)、疏水性胆固醇和亲水性聚乙二醇(PEG)共价修饰聚阳离子对其的影响。还通过用血清白蛋白包覆表面来调节这三种不同纳米颗粒的表面电荷。我们发现,基于正电荷聚合物 AMD3100 CXCR4 拮抗剂(PAMD)和用 TFTA 修饰的 PAMD(mPAMD-TFTA)/siRNA 的混合物的带正电荷的含氟粒子具有疏脂性,在体外显示出最佳的细胞摄取和转染效率。在同种原位 PDAC 模型中对纳米颗粒的分布评估表明,含氟制剂在 IP 给药后也能实现 PDAC 肿瘤的最高积累。用 PAMD 抑制 CXCR4 和 siRNA 下调 PLK1 联合治疗,mPAMD-TFTA/siPLK1 的治疗显著抑制了原发性和转移性 PDAC 肿瘤。总的来说,我们的研究为 PDAC 中 siRNA 的 IP 递药提供了深入的见解,并指导了纳米颗粒的设计。